Why is Glenmark Pharma falling/rising?

As of 11-Jul, Glenmark Pharmaceuticals Ltd. is experiencing a significant rise in its stock price, currently at Rs 2,181.55, reflecting an increase of 276.4 points or 14.51%. The stock has recently hit a new 52-week and all-time high of Rs 2,286.15, demonstrating strong performance today with a 10% gap up at the open and an intraday high reaching 20%. Over the past week, the stock has gained 19.11%, and it has consistently outperformed the sector by 13.93%. The company has shown robust performance over the last three years, with a staggering 458.94% return, and has maintained a low Debt to EBITDA ratio of 1.00 times, indicating a strong ability to service its debt. Additionally, the company has reported positive results for the last four consecutive quarters, further bolstering investor confidence.
In the broader market context, Glenmark Pharmaceuticals has significantly outperformed the Sensex, which has seen a decline of 1.12% over the past week, while Glenmark's stock has risen by 19.11%. This stark contrast highlights the stock's strong momentum amid a generally weak market. The rising investor participation, evidenced by a 72.44% increase in delivery volume, and high institutional holdings at 37.8% suggest that informed investors are confident in the company's fundamentals. Overall, the combination of strong financial performance, positive market sentiment, and favorable trading conditions has contributed to the stock's upward trajectory.